Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Therapy in Genotype 3 Hepatitis C
NCT01095445Phase 3Terminated
- Sponsor
- University Health Network
- Start
- Feb 2010
- Primary completion
- Jun 2011
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (2 arms), sponsored by University Health Network. Primary endpoint: Sustained Virologic Response. Started Feb 2010; status: terminated.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01095445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01095445.